Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease

References

• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–e621. doi:10.1161/CIR.0000000000001123
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80:2361–2371. doi:10.1016/j.jacc.2022.11.005
   PubMed Web of Science ®Google Scholar
• Gu J, Sanchez R, Chauhan A, Fazio S, Wong N. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update. Am J Prev Cardiol. 2022;10:100336. doi:10.1016/j.ajpc.2022.100336
   PubMedGoogle Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–2472. doi:10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046–e1081. doi:10.1161/CIR.0000000000000624
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Shapiro MD, Bhatt DL. ”Cholesterol-Years” for ASCVD risk prediction and treatment. J Am Coll Cardiol. 2020;76:1517–1520. doi:10.1016/j.jacc.2020.08.004
   PubMed Web of Science ®Google Scholar
• Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC health promotion series. J Am Coll Cardiol. 2018;72:1141–1156. doi:10.1016/j.jacc.2018.06.046
   PubMed Web of Science ®Google Scholar
• Michos ED, McEvoy JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med. 2019;381:1557–1567. doi:10.1056/NEJMra1806939
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. doi:10.1016/S0140-6736(10)61350-5
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207. doi:10.1056/NEJMoa0807646
   PubMed Web of Science ®Google Scholar
• Patel KV, Pandey A, de Lemos JA. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine. Circulation. 2018;137:2551–2553. doi:10.1161/CIRCULATIONAHA.118.035289
   PubMed Web of Science ®Google Scholar
• Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021;6:1060. doi:10.1001/jamacardio.2021.1810
   Web of Science ®Google Scholar
• Ray KK, Haq I, Bilitou A, Catapano AL; Investigators TS. Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study. Eur Heart J. 2021:42. doi:10.1093/eurheartj/ehab724.2580
   Web of Science ®Google Scholar
• Khan SU, Khan MU, Virani SS, et al. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;28:2001–2009. doi:10.1093/eurjpc/zwaa093
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397. doi:10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722. doi:10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107. doi:10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial. JAMA Cardiol. 2017;2:547–555. doi:10.1001/jamacardio.2017.0083
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411–1416. doi:10.1016/j.jacc.2005.04.064
   PubMed Web of Science ®Google Scholar
• Karagiannis AD, Mehta A, Dhindsa DS, et al. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021;42:2154–2169. doi:10.1093/eurheartj/ehaa1080
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146:1109–1119. doi:10.1161/CIRCULATIONAHA.122.061620
   PubMed Web of Science ®Google Scholar
• Gaine SP, Quispe R, Patel J, Michos ED. New strategies for lowering low-density lipoprotein cholesterol for cardiovascular disease prevention. Curr Cardiovasc Risk Rep. 2022;16:69–78. doi:10.1007/s12170-022-00694-y
   PubMed Web of Science ®Google Scholar
• Writing C, Lloyd-Jones DM, Morris PB, et al. 2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366–1418. doi:10.1016/j.jacc.2022.07.006
   PubMed Web of Science ®Google Scholar
• Michos ED, Ferdinand KC. Lipid-lowering for the prevention of cardiovascular disease in the new era: a practical approach to combination therapy. EAJ. 2022;1:eaj_22005.
   Google Scholar
• Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther. 2021;15:1955–1963. doi:10.2147/DDDT.S251865
   PubMed Web of Science ®Google Scholar
• Warden BA, Duell PB. Inclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins. J Cardiovasc Pharmacol. 2021;78:e157–e174. doi:10.1097/fjc.0000000000001053
   PubMed Web of Science ®Google Scholar
• Soffer D, Stoekenbroek R, Plakogiannis R. Small interfering ribonucleic acid for cholesterol lowering - inclisiran: inclisiran for cholesterol lowering. J Clin Lipidol. 2022;16:574–582. doi:10.1016/j.jacl.2022.06.009
   PubMed Web of Science ®Google Scholar
• Alshaer W, Zureigat H, Al Karaki A, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905:174178. doi:10.1016/j.ejphar.2021.174178
   PubMed Web of Science ®Google Scholar
• Katzmann JL, Packard CJ, Chapman MJ, Katzmann I, Laufs U. Targeting RNA with antisense oligonucleotides and small interfering RNA in dyslipidemias: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76:563–579. doi:10.1016/j.jacc.2020.05.070
   PubMed Web of Science ®Google Scholar
• Di Fusco SA, Colivicchi F, Maggioni AP, et al. Inclisiran: a new pharmacological approach for hypercholesterolemia. Rev Cardiovasc Med. 2022;23:375. doi:10.31083/j.rcm2311375
   Web of Science ®Google Scholar
• Levin AA. Targeting Therapeutic Oligonucleotides. N Engl J Med. 2017;376:86–88. doi:10.1056/NEJMcibr1613559
   PubMed Web of Science ®Google Scholar
• German CA, Shapiro MD. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. BioDrugs. 2020;34:1–9. doi:10.1007/s40259-019-00399-6
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–1440. doi:10.1056/NEJMoa1615758
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–1530. doi:10.1056/NEJMoa1913805
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–1519. doi:10.1056/NEJMoa1912387
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Leqvio Access and Reimbursement;. 2022. Available from: https://www.leqvio-access.com/coveragetypes. Accessed June 27, 2023.
   Google Scholar
• Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4:1067–1075. doi:10.1001/jamacardio.2019.3502
   PubMed Web of Science ®Google Scholar
• Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77:1182–1193. doi:10.1016/j.jacc.2020.12.058
   PubMed Web of Science ®Google Scholar
• Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109–119. doi:10.1016/S2213-8587(22)00353-9
   PubMed Web of Science ®Google Scholar
• Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44:129–138. doi:10.1093/eurheartj/ehac594
   PubMed Web of Science ®Google Scholar
• US Food & Drug Administration. Drugs@FDA - Leqvio (inclisiran). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214012Orig1s000TOC.cfm. Accessed June 27, 2023.
   Google Scholar
• Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95:77–89. doi:10.1016/j.mayocp.2019.08.021
   PubMed Web of Science ®Google Scholar
• Novartis. LEQVIO (inclisiran) [package insert]. Available from: https://www.novartis.com/us-en/sites/novartis_us/files/leqvio.pdf. Accessed November 24, 2022.
   Google Scholar
• Novartis. Alternate injection center step-by-step guide. Available from: https://www.leqvio-access.com/assets/pdf/LEQVIO-US-Alternate-Injection-Center-Guide_168613.pdf. Accessed November 24, 2022.
   Google Scholar
• Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic. J Clin Lipidol. 2022;17:73–77. doi:10.1016/j.jacl.2022.10.009
   PubMed Web of Science ®Google Scholar